Overview and Epidemiology

Familial Mediterranean Fever (FMF) is a rare, autosomal recessive autoinflammatory disorder characterized by recurrent episodes of fever and inflammation. It primarily affects individuals of Mediterranean and Middle Eastern descent, including those of Armenian, Turkish, Arab, Sephardic Jewish, and Greek origin. FMF is one of the most common hereditary autoinflammatory syndromes worldwide, with a carrier frequency as high as 1 in 5 among certain populations in the Middle East and North Africa.

The disease is caused by mutations in the MEFV (Mediterranean Fever) gene, located on chromosome 16p13.3. This gene encodes the protein pyrin, which plays a crucial role in regulating the innate immune system, particularly in modulating the inflammasome pathway. Dysfunctional pyrin due to MEFV mutations leads to uncontrolled activation of the inflammatory cascade, resulting in periodic fever and systemic inflammation.

Recent epidemiological studies suggest that FMF may be more prevalent than previously thought, with estimates indicating a prevalence of approximately 1 in 200 to 1 in 1,000 in high-risk populations. Notably, over 80% of affected individuals experience their first clinical episode before the age of 20, and about 75% have their initial attack by age 10. This early onset pattern underscores the importance of early diagnosis and intervention, especially in pediatric populations.

Genetic Basis and Molecular Mechanisms

The MEFV gene is highly polymorphic, with over 200 known mutations identified to date. The most common pathogenic variants include M694V, M694I, V726A, E148Q, and M680I. Among these, the M694V mutation is strongly associated with more severe disease, earlier onset, and higher risk of amyloidosis. However, genotype-phenotype correlations remain complex, as some individuals with two mutated alleles may have mild or even asymptomatic presentations, while others with single mutations may exhibit clinical symptoms.

Recent genomic research has revealed that MEFV mutations may contribute to the pathogenesis of other autoimmune and inflammatory conditions, including rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. This suggests a broader role for pyrin dysfunction in immune dysregulation beyond FMF. Additionally, epigenetic factors and environmental triggers—such as infections or stress—may influence disease expression and attack frequency.

Genetic counseling is strongly recommended for newly diagnosed patients and their families, particularly when planning for reproduction. Preconception testing, carrier screening, and prenatal diagnosis are available and can inform reproductive decisions. Whole-exome sequencing and next-generation sequencing panels are increasingly used in clinical settings to identify MEFV variants and other potential genetic contributors.

Clinical Presentation and Symptomatology

FMF typically presents with recurrent, self-limiting episodes of fever, lasting 12–72 hours, often followed by a symptom-free interval that can range from days to years. The frequency and severity of attacks vary widely among individuals and even within families. In many cases, symptoms begin in childhood or adolescence, with the peak incidence occurring between ages 5 and 15.

Common manifestations include:

• Abdominal pain (present in 80–90% of cases), often severe and mimicking acute appendicitis or peritonitis.
• Thoracic pain (pleuritic or pericarditic), which may resemble pneumonia or cardiac conditions.
• Arthritis affecting large joints (e.g., knee, ankle, wrist), typically asymmetric and non-erosive.
• Erythematous rash (often described as erysipelas-like), commonly appearing on the lower legs and sometimes accompanied by fever.
• Headache and malaise during attacks.

Notably, up to 50% of patients report prodromal symptoms—such as fatigue, nausea, or mild discomfort—preceding the full-blown attack. This variability in presentation can lead to diagnostic delays or misdiagnoses, particularly in atypical cases.

Complications and Long-Term Risks

The most serious complication of untreated or inadequately managed FMF is secondary amyloidosis, a condition in which misfolded proteins (amyloid A, or AA) accumulate in vital organs, primarily the kidneys. Amyloidosis can lead to nephrotic syndrome, progressive renal failure, and ultimately end-stage renal disease (ESRD). The risk of amyloidosis is significantly reduced with early and consistent treatment.

Recent longitudinal studies indicate that the cumulative incidence of amyloidosis in untreated FMF patients is approximately 10–20% over a lifetime. However, with widespread use of colchicine prophylaxis, this risk has decreased dramatically—now estimated at less than 2% in patients adhering to treatment.

Other potential complications include chronic kidney disease, cardiovascular involvement (due to amyloid deposition), and reduced quality of life due to recurrent illness and medication side effects.

Diagnosis: Clinical and Laboratory Approaches

Diagnosis of FMF is primarily clinical,, based on the Tel Hashomer criteria—a widely used scoring system that includes fever duration, attack frequency, abdominal pain, arthritis, response to colchicine, and family history. A score of ≥8 is considered highly suggestive of FMF.

Key diagnostic steps include:

1. Clinical Evaluation: A detailed history of recurrent fevers, abdominal pain, joint pain, and rash, with attention to age of onset and familial patterns.
2. Family History: Since FMF is autosomal recessive, a family history of similar symptoms or confirmed FMF increases diagnostic likelihood.
3. Laboratory Tests:
   • Complete blood count (CBC): Elevated white blood cell count (leukocytosis) during attacks.
   • Inflammatory markers: Elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) during episodes.
   • Urinalysis: Presence of proteinuria or hematuria may indicate early renal involvement due to amyloidosis.
4. Genetic Testing:
   • DNA sequencing of the MEFV gene can confirm diagnosis. However, due to the high frequency of variants of uncertain significance (VUS) and the possibility of false negatives (especially in heterozygous individuals or those with non-classical mutations), genetic testing should not be used in isolation.
   • Next-generation sequencing (NGS) panels and targeted gene analysis are increasingly used for comprehensive evaluation.

It is critical to avoid misdiagnosis—especially in children with abdominal pain, where FMF may be mistaken for appendicitis, leading to unnecessary surgery. A high index of suspicion and early referral to a rheumatologist or immunologist are essential.

Treatment and Management Strategies

The cornerstone of FMF management is colchicine, a medication originally used for gout and pericarditis. It has been shown to dramatically reduce the frequency and severity of attacks and prevent amyloidosis.

• Dosing: The standard prophylactic dose is 0.5–2.0 mg/day, adjusted based on age, weight, and response. Children typically start at 0.5–1.0 mg/day.
• Mechanism: Colchicine inhibits microtubule polymerization, reducing neutrophil chemotaxis and inflammasome activation. It may also modulate pyrin function, though the exact mechanism remains under investigation.
• Safety and Side Effects: Common side effects include gastrointestinal disturbances (diarrhea, nausea, abdominal cramps). Rare but serious complications include myopathy and neuropathy, especially at high doses. Monitoring of liver and kidney function and creatine kinase levels is recommended.

For patients with colchicine-resistant or intolerant FMF, alternative therapies are available:

• Anakinra: An interleukin-1 receptor antagonist, effective in controlling flares. Daily subcutaneous injections are typically used.
• Canakinumab: A humanized monoclonal antibody against interleukin-1β (IL-1β), approved for FMF in several countries. It has shown excellent efficacy in reducing attack frequency and improving quality of life in colchicine-resistant patients.
• Rilonacept and IL-1-targeting biologics: Emerging therapies currently under investigation.

In rare cases, interferon therapy has been explored, though evidence remains limited. Biologics targeting the IL-1 pathway have also been studied in other autoinflammatory syndromes such as Muckle-Wells syndrome (MWS), cryopyrin-associated periodic syndromes (CAPS), and hyperimmunoglobulin D syndrome (HIDS), with promising results.

Pregnancy and FMF

The safety of colchicine during pregnancy is a topic of ongoing research. While early studies raised concerns about potential teratogenicity, more recent data from large cohort studies and registries suggest that colchicine is safe for use during pregnancy, especially when taken at low prophylactic doses. Most rheumatologists now recommend continuing colchicine during pregnancy to prevent flares, which can pose greater risks to both mother and fetus than the medication itself. Close monitoring by a multidisciplinary team is advised.

Prognosis and Long-Term Outlook

With early diagnosis and consistent treatment, the prognosis for FMF is excellent. Most patients achieve remission, with near-normal life expectancy and quality of life. Colchicine therapy reduces the frequency of attacks by up to 90% and nearly eliminates the risk of amyloidosis.

However, challenges remain, particularly in resource-limited settings where access to genetic testing and biologic therapies is limited. Additionally, non-adherence to treatment—due to cost, side effects, or lack of awareness—remains a significant barrier.

Psychosocial support is crucial, especially for children and adolescents. Frequent absences from school, social isolation, and the burden of lifelong medication can impact mental health and development. Collaboration with educators, school counselors, and social workers is essential to support academic and emotional well-being.

Conclusion

Familial Mediterranean Fever is a complex but manageable autoinflammatory disorder that requires a multidisciplinary approach. Advances in genetics, immunology, and targeted therapies have transformed FMF from a potentially fatal condition to a chronic but controllable disease. Early recognition, accurate diagnosis, and long-term adherence to colchicine therapy are key to preventing complications and ensuring optimal outcomes. Ongoing research into novel biologics and personalized treatment strategies promises to further improve the lives of individuals affected by FMF.